The Delaware Supreme Court rejected the legitimacy of expert testimony linking Zantac to cancer, Jef Feeley of Bloomberg reports. The judge agreed with arguments from companies including GSK (GSK), Pfizer (PFE) and Boehringer Ingelheim that a trial judge overseeing 75,000 lawsuits erred in allowing the cases to proceed to trial, according to Bloomberg.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK’s Belimumab Study: A Potential Game-Changer for SSc-ILD Treatment
- GSK’s Promising Phase 2b Study on Atopic Dermatitis Treatment
- GSK begins shipping doses of trivalent seasonal influenza vaccines
- GSK Pharma call volume above normal and directionally bullish
- GSK’s Belimumab Study: A Potential Game-Changer for Systemic Sclerosis Treatment?